Pharmaceuticals policy

Almirall receives European Commission approval of Klisyri®▼ (tirbanibulin), an innovative topical treatment for actinic keratosis

Retrieved on: 
Monday, July 19, 2021
Pharmaceuticals policy, Health care, Chemistry, Health, Actinic keratosis, Dermatology, Swissmedic, Tirbanibulin, Keratosis, Almirall, Marketing authorisation, Actinism

"The approval of Klisyrirepresents a breakthrough for actinic keratosis patients, who seek new treatments that could offer them better tolerability and short treatment duration.

Key Points: 
  • "The approval of Klisyrirepresents a breakthrough for actinic keratosis patients, who seek new treatments that could offer them better tolerability and short treatment duration.
  • In addition, Almirall submitted Klisyri for a marketing authorisation in Switzerland in December 2020 and the dossier is currently under review by Swissmedic.
  • The company has already submitted in Great Britain via the European Commission Decision Reliance Procedure.
  • Chetty P, Choi F, Mitchell T. Primary care review of actinic keratosis and its therapeutic options: a global perspective.

ContraFect Announces Multiple Presentations of New Research Data From Its Pipeline of Direct Lytic Agents at the 31st ECCMID

Retrieved on: 
Monday, July 19, 2021
Lysin, Health sciences, Antimicrobial, Infection, Health, Medicine, Evolutionary biology, Pharmaceuticals policy, Veterinary medicine

The data presented at ECCMID further illustrates the potential utility of our lysin therapeutic modalities to address important unmet medical needs.

Key Points: 
  • The data presented at ECCMID further illustrates the potential utility of our lysin therapeutic modalities to address important unmet medical needs.
  • Our findings continue to highlight the potent antimicrobial activity of lysins against virulent, highly-resistant bacterial strains known to cause debilitating and life-threatening infections.
  • We look forward to additional new data as we continue to advance these programs.
  • Important factors that could cause actual results to differ include, among others, our ability to develop treatments for drug-resistant infectious diseases.

Global Digital Pathology Market (2021 to 2026) - Integration of AI into Healthcare Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Monday, July 19, 2021
Health, Biotechnology, Life sciences, Academic disciplines, Articles, Biotechnology, Clinical research, Contract research organization, Pharmaceutical industry, Pharmaceuticals policy, Digital pathology, Compound annual growth rate, Pathology

The global digital pathology market by revenue is expected to grow at a CAGR of over 10% during the period 2020-2026.

Key Points: 
  • The global digital pathology market by revenue is expected to grow at a CAGR of over 10% during the period 2020-2026.
  • The incorporation of artificial intelligence further extends the limits of pathology studies and data management, helping to increase the acceptance of digital pathology.
  • The following factors are likely to contribute to the growth of the digital pathology market during the forecast period:
    The study considers the global digital pathology market's present scenario and its market dynamics for the period 2020-2026.
  • The global digital pathology market by contract research organizations (CRO) expects to grow at a CAGR of approx.

NovaBay Pharmaceuticals Partners with Harrow Health’s ImprimisRx® to Promote Prescription Avenova

Retrieved on: 
Monday, July 19, 2021
Pharmaceutical, Health, Optical, Health care, Pharmaceuticals policy, Medical specialties, Health, Harrow Health, Optometry, Pharmaceutical industry in China, Ophthalmology, Harrow Health, NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®, HARROW HEALTH, NOVABAY PHARMACEUTICALS, INC.: GOING BEYOND ANTIBIOTICS®

(NYSE American: NBY), a pharmaceutical company focusing on commercializing Avenova for the eye care market, announces it has partnered with ImprimisRx, one of the nations leading ophthalmology-focused pharmaceutical businesses, to promote prescription Avenova.

Key Points: 
  • (NYSE American: NBY), a pharmaceutical company focusing on commercializing Avenova for the eye care market, announces it has partnered with ImprimisRx, one of the nations leading ophthalmology-focused pharmaceutical businesses, to promote prescription Avenova.
  • Under the new agreement with ImprimisRx, we can now cost-efficiently expand Avenovas reach within the prescription channel by better engaging with ophthalmologists and optometrists, making prescription Avenova even more accessible than ever before.
  • Avenova is a compelling addition to our expanding ImprimisRx ophthalmic product portfolio, said John Saharek, President of ImprimisRx.
  • Harrow Health also holds equity positions in Eton Pharmaceuticals, Surface Ophthalmics and Melt Pharmaceuticals, all of which started as Harrow Health subsidiaries.

Global Over the Counter (OTC) Drugs Markets, 2015-2020 & 2021-2025: Cough, Cold, and Flu, Analgesics, Dermatology Products, Vitamins, Mineral, and Supplements - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 15, 2021
Health, Pharmaceutical, Finance, Money, Health sciences, Pharmaceuticals policy, Financial markets, Drugs, Mathematical finance, Over-the-counter, Stock market, Medication

The Global Over the Counter (OTC) Drugs Market exceeded USD 140 billion in 2019 and is expected to grow at a CAGR of around 8.23% during the forecast period.

Key Points: 
  • The Global Over the Counter (OTC) Drugs Market exceeded USD 140 billion in 2019 and is expected to grow at a CAGR of around 8.23% during the forecast period.
  • The Global Over the Counter (OTC) Drugs Market is driven by rising health consciousness among the population across the globe.
  • The availability and affordability of these medicines has further increased the adoption rates of the OTC drugs in the market.
  • The Global Over the Counter (OTC) Drugs Market is segmented based on product, dosage form, distribution channel, company, and region.

Global Pharmaceutical Contract Manufacturing Market Trajectory & Analytics to 2027 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 15, 2021
Health, Pharmaceutical, Health sciences, Health care, Health, Pharmaceuticals policy, Pharmaceutical industry in China, Pharmacy in China, Science and technology in the People's Republic of China, Pharmaceutical industry in India, Pharmaceutical industry

The "Pharmaceutical Contract Manufacturing - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Pharmaceutical Contract Manufacturing - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Amid the COVID-19 crisis, the global market for Pharmaceutical Contract Manufacturing estimated at US$100 Billion in the year 2020, is projected to reach a revised size of US$130.2 Billion by 2026, growing at a CAGR of 4.6% over the analysis period.
  • Growth in the global market is set to be driven by positive trends in the broader pharmaceuticals market which is in turn driven by growth in the emerging markets.
  • The U.S. Market is Estimated at $31.6 Billion in 2021, While China is Forecast to Reach $21.1 Billion by 2026
    The Pharmaceutical Contract Manufacturing market in the U.S. is estimated at US$31.6 Billion in the year 2021.

Dry Eye Medication Global Market Opportunities and Strategies to 2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 15, 2021
Health, Optical, Pharmacies, Health sciences, Online pharmacy, Pharmaceuticals policy, Health care, Hospital pharmacy, Health

The "Dry Eye Medication Global Market Opportunities and Strategies to 2030: COVID-19 Impact and Recovery" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Dry Eye Medication Global Market Opportunities and Strategies to 2030: COVID-19 Impact and Recovery" report has been added to ResearchAndMarkets.com's offering.
  • The dry eye medication market is segmented by type of distribution channel into hospital pharmacies, eye health clinics, retail pharmacies and online pharmacies.
  • The dry eye medication market is segmented by delivery system into liquid drops, gel, eye ointment and others.
  • North America was the largest region in the dry eye medication market, accounting for 31.3% of the global market in 2020.

RxS, LLC Expands U.S. Footprint in Fort Lauderdale, FL

Retrieved on: 
Thursday, July 15, 2021
Health sciences, Pharmacy, Health care, Health, Pharmaceuticals policy, Clinical pharmacology, Drugs, Prescription drug, Pharmaceutical industry, PDMA

"This is an exciting time for RxS," commented Mark Jara, RxS Principal and Managing Director.

Key Points: 
  • "This is an exciting time for RxS," commented Mark Jara, RxS Principal and Managing Director.
  • "Expanding our U.S. footprint in Fort Lauderdale was a strategic decision to help our company support the growing demand for our services, including virtual brand awareness platforms.
  • RxS LLC is the leading provider of multi-channel sample management, ensuring regulatory compliance while lessening the administrative burden of the Prescription Drug Marketing Act (PDMA).
  • RxS focuses on technology-driven, proprietary services and innovative software solutions that empower success for pharmaceutical and biotech companies around the globe.

Genexa, the World’s First and Only Clean Medicine Company, Announces Record-breaking Series A Round

Retrieved on: 
Wednesday, July 14, 2021
Home Goods, Women, Retail, Pharmaceutical, MEN, Baby, Maternity, Family, Finance, Consumer, Professional services, Fitness & Nutrition, Department Stores, Entertainment, Alternative medicine, Health, Supermarket, Specialty, Celebrity, Health sciences, Health care, Health, Pharmaceuticals policy, Drug Safety, Drugs, Over-the-counter drug, Pharmaceutical industry, Unilever

Genexa , the worlds first clean, over-the-counter pharmaceutical company, has just completed its unprecedented $60 million Series A of funding to advance its market leadership in this emerging space.

Key Points: 
  • Genexa , the worlds first clean, over-the-counter pharmaceutical company, has just completed its unprecedented $60 million Series A of funding to advance its market leadership in this emerging space.
  • Jared Stein, Co-Founder and Managing Partner of Monogram Capital led the round and was joined by some of the worlds most well-regarded investors, including Unilever Ventures, Verlinvest, Northcastle Partners, and Point King Capital.
  • Genexa is heralding in a sea change moment in medicine, giving consumers access to the first clean, better-for-you, efficacious option ever in the OTC market.
  • All of our products are made to the highest standards of medicine with no artificial dyes, common allergens, or unnecessary inactive ingredients.

CTI Clinical Trial and Consulting Services Announce Acquisition of European Based Dynakin

Retrieved on: 
Wednesday, July 14, 2021
Health, FDA, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Health sciences, Contract research organizations, Health, Clinical research, Life sciences, Pharmaceutical industry, Biotechnology, Pharmaceuticals policy, ERT, Clinical trial

CTI Clinical Trial and Consulting Services (CTI), a global, privately held, full-service contract research organization announces the acquisition of Dynakin , a contract research organization with a GLP biolab and model-based drug development services that has nearly two decades of experience and strong local expertise across Europe.

Key Points: 
  • CTI Clinical Trial and Consulting Services (CTI), a global, privately held, full-service contract research organization announces the acquisition of Dynakin , a contract research organization with a GLP biolab and model-based drug development services that has nearly two decades of experience and strong local expertise across Europe.
  • Dynakins CRO services will be merged into CTIs European clinical team.
  • Dynakin co-founders Dr. Monica Rodriguez and Dr. Nerea Leal will be joining CTI in new roles that will be integral to the companys growth.
  • CTI Clinical Trial and Consulting Services is a global, privately held, full-service contract research organization (CRO), delivering a complete spectrum of clinical trial and consulting services throughout the lifecycle of development, from concept to commercialization.